Monoclonal Antibodies

1. Definition

Monoclonal antibodies (mAbs) are a homogeneous population of immunoglobulins produced by a single clone of B lymphocytes. Because they originate from one unique plasma cell clone, all molecules are structurally identical and recognize a single specific epitope on a given antigen.

This strict specificity distinguishes monoclonal antibodies from polyclonal antibodies, which represent a heterogeneous mixture of immunoglobulins produced by multiple B-cell clones and capable of recognizing several epitopes on the same antigen.

Monoclonal antibodies therefore provide high antigen specificity, reproducibility, and consistent biochemical properties, which make them valuable tools in biomedical research, diagnostics, and therapeutics.

2. Advantages and Limitations

Advantages

Monoclonal antibodies present several major advantages:

  • High specificity, since each antibody recognizes a single antigenic epitope.

  • High affinity and reproducibility in antigen binding.

  • Unlimited production, because antibody-producing hybridoma cells can be immortalized and maintained indefinitely in culture.

  • Reduced use of experimental animals, compared with polyclonal antibody production.

Limitations

Despite their advantages, monoclonal antibody production presents certain limitations:

  • The production process is technically complex.

  • Longer development time: monoclonal antibody production generally requires 3–6 months, whereas polyclonal antibodies can be obtained within 4–8 weeks.

  • Higher cost and specialized laboratory expertise are required.

3. Principle of Monoclonal Antibody Production

The production of monoclonal antibodies is based on the hybridoma technology, which involves the fusion of antibody-producing B cells with immortal tumor cells.

Fusion Partners

Two main cell types participate in the fusion process:

1. B lymphocytes (plasma cells)
These cells are isolated from secondary lymphoid organs such as the spleen or lymph nodes of an immunized animal. They produce antibodies specific to the target antigen and possess the enzyme HGPRT (hypoxanthine-guanine phosphoribosyl transferase).

2. Myeloma cells
These are immortal tumor cells derived from plasma cell malignancies. They lack the ability to produce immunoglobulins (Ig⁻ mutants) and are deficient in the HGPRT enzyme. Their primary contribution is their capacity for unlimited proliferation.

Fusion between these two cell types generates hybridoma cells, which combine the antibody production ability of B cells with the immortality of myeloma cells.

4. Immunization Phase

Before hybridoma formation, animals such as mice or rats are immunized with the target antigen to stimulate the production of antigen-specific B cells.

Key parameters influencing immunization include:

  • Antigen purity, ensuring removal of contaminants.

  • Antigen dose and formulation.

  • Use of adjuvants, which enhance the immune response.

  • Route and number of injections.

Animals used for immunization and hybridoma production must be genetically identical (syngeneic strains) to avoid immunological incompatibility.

5. Hybridoma Formation

Antibody-secreting plasma cells are fused with myeloma cells to produce hybridomas.

Membrane fusion is commonly induced by polyethylene glycol (PEG), which promotes the merging of cell membranes. The resulting hybridomas have the ability to:

  • Proliferate indefinitely in culture

  • Produce large quantities of specific monoclonal antibodies

Hybridomas replicate more rapidly than normal plasma cells and can continuously secrete antibodies.

6. Fusion Techniques

Chemical Fusion

The most widely used method employs polyethylene glycol (PEG).

Characteristics:

  • Induces fusion of cytoplasmic membranes

  • High fusion efficiency

  • Often combined with DMSO, which improves cell viability

Physical Fusion (Electrofusion)

Fusion can also be induced using electric pulses, which temporarily create pores in cell membranes.

Characteristics:

  • More precise and less destructive to cells

  • Requires specialized and costly equipment

7. Selection of Hybridoma Cells

Following fusion, the mixed cell population is cultured in HAT selective medium, which contains:

  • Hypoxanthine

  • Aminopterin

  • Thymidine

This medium allows selective survival of hybridoma cells.

Mechanism of Selection

Mammalian cells synthesize nucleotides through two metabolic pathways:

  1. De novo pathway

  2. Salvage pathway

Aminopterin blocks the de novo pathway, forcing cells to rely on the salvage pathway, which requires enzymes such as:

  • HGPRT

  • Thymidine kinase (TK)

Consequences in HAT medium:

  • Unfused myeloma cells lack HGPRT and cannot use the salvage pathway → they die.

  • Unfused plasma cells possess HGPRT but have limited lifespan → they die naturally.

  • Hybridoma cells inherit HGPRT from plasma cells and immortality from myeloma cells → they survive and proliferate.

8. Cloning and Screening of Hybridomas

After selection, hybridomas are distributed into microtiter plates, ideally with one cell per well.

Clonal expansion can be achieved through:

  • Agar or agarose cloning

  • Limiting dilution cloning, the most commonly used technique.

Screening methods are then used to identify hybridomas producing the desired antibody.

Screening Techniques

Common immunological screening methods include:

  • Immunoprecipitation techniques (Ouchterlony, Mancini methods)

  • Radioimmunoassay (RIA)

  • Enzyme immunoassay (EIA) such as ELISA

  • Western blot analysis

  • Flow cytometry (cell sorting)

9. Effector Functions of Antibodies

All antibodies possess two fundamental biological properties:

  1. Specific antigen binding, mediated by the variable region of the antibody.

  2. Effector functions, mediated by the Fc region, including:

    • Activation of the complement system

    • Opsonization and stimulation of phagocytosis

    • Recruitment of immune effector cells

10. Development of Therapeutic Monoclonal Antibodies

The first therapeutic monoclonal antibody, muromonab-CD3, was introduced in 1981 for the treatment of acute organ transplant rejection.

However, early monoclonal antibodies derived from murine hybridomas had several disadvantages:

  • Short serum half-life

  • High immunogenicity in humans

Advances in molecular biotechnology during the 1980s enabled the development of improved antibody formats:

  • Chimeric antibodies

  • Humanized antibodies

  • Fully human monoclonal antibodies

These modifications significantly improved therapeutic performance by:

  • Reducing immunogenicity

  • Increasing serum half-life

  • Enhancing effector functions

For example, the half-life of murine antibodies (less than 20 hours) can be extended to several days, approaching the 21-day half-life of endogenous human IgG.

11. Nomenclature and Applications

Therapeutic monoclonal antibodies follow a standardized nomenclature ending with the suffix -mab (monoclonal antibody), such as rituximab.

Research Applications

Monoclonal antibodies are widely used in biotechnology and biomedical research, including:

  • Flow cytometry

  • Immunohistochemistry

  • Cell lineage and marker identification

  • Study of pathological cells

  • Antigen purification

Diagnostic Applications

They are essential in many diagnostic assays:

  • ELISA tests

  • Radioimmunoassays

  • Immunohematology testing

  • Medical imaging techniques such as immunoscintigraphy

  • Pregnancy tests

Therapeutic Applications

Monoclonal antibodies are currently used in several clinical fields:

  • Cancer therapy, targeting tumor cells

  • Immunosuppressive therapy for autoimmune diseases and transplant rejection

  • Cardiology, particularly in antithrombotic therapy

  • Infectious diseases, including antiviral prophylaxis

  • Allergy treatment, such as severe asthma management

Currently, dozens of monoclonal antibodies are approved for clinical use, while many others remain under clinical investigation.

12. Clinical Perspectives and Limitations

Monoclonal antibodies represent a major advance in targeted therapy, offering highly specific treatment options for severe diseases where conventional therapies may be insufficient.

However, several challenges remain:

  • High production costs

  • Long-term treatment requirements

  • Limited long-term safety data for some molecules

Therefore, continuous clinical monitoring and pharmacovigilance are essential to fully evaluate the long-term benefits and potential risks associated with monoclonal antibody therapies.